Brief: Idera Pharmaceuticals Inc Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
01/12/2021 22:07
Dec 1 (Reuters) - Idera Pharmaceuticals Inc IDRA.O :
* IDERA PHARMACEUTICALS INC - ON NOVEMBER 26, RECEIVED
NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD
Further company coverage: IDRA.O
Recent news on Aceragen
See all newsBrief: Aceragen CEO John Taylor's Employment With Co Terminated
Brief: Aceragen Inc To Delist From The Nasdaq Stock Market
Aceragen Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Aceragen Board Determined It Is In Best Interests Of Co,To Effect Transfer,Assignment Of All Of Co's Assets To Assignee
Aceragen Inc reports results for the quarter ended in March - Earnings Summary